Cargando…
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
In patients with existing ovarian function, there are some special aspects to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-negative (HR pos./HER2 neg.) breast cancer. Treatment options include tamoxifen with or without a GnRH analog, and aromatase inhibit...
Autores principales: | Müller, Volkmar, Fasching, Peter A., Nabieva, Naiba, Fehm, Tanja N., Thill, Marc, Schmidt, Marcus, Kühn, Thorsten, Banys-Paluchowski, Maggie, Belleville, Erik, Juhasz-Böss, Ingolf, Untch, Michael, Kolberg, Hans-Christian, Harbeck, Nadia, Aktas, Bahriye, Stickeler, Elmar, Kreuzeder, Julia, Hartkopf, Andreas D., Janni, Wolfgang, Ditsch, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442909/ https://www.ncbi.nlm.nih.gov/pubmed/37614683 http://dx.doi.org/10.1055/a-2073-1887 |
Ejemplares similares
-
Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
por: Aktas, Bahriye, et al.
Publicado: (2022) -
Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2022) -
Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2023) -
Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2023) -
Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2022)